Sunshine Biopharma is conducting a public offering of units comprised of one share of common stock and one warrant exercisable for one share of common stock. The offering, however, is contingent upon the approval of the company's application for listing on the Nasdaq.
The company's stock currently trades on the Over-the-Counter Markets pink sheets under the ticker symbol "SBFM." If its application is approved, it will trade on the Nasdaq under the same ticker symbol.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.93 |
|---|---|
| 52-week range | $1.90 - $265.00 |
| 50-day moving average | $2.61 |
| 200-day moving average | $3.96 |
| Wall St. target price | $300.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-127.90 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.93 from 2025-03-14
| 1 week (2025-03-07) | -19.25% |
|---|---|
| 1 month (2025-02-14) | -23.11% |
| 3 months (2024-12-17) | -29.56% |
| 6 months (2024-09-17) | -31.80% |
| 1 year (2024-03-15) | 3,116.67% |
|---|---|
| 2 years (2023-03-16) | -99.89% |
| 3 years (2022-03-16) | 6560 |
| 5 years (2020-03-16) | 1600 |
| Revenue TTM | $33 million |
|---|---|
| Gross profit TTM | $10.1 million |
| Return on assets TTM | -10.75% |
| Return on equity TTM | -17.98% |
| Profit margin | -12.82% |
| Book value | $12.52 |
| Market Capitalization | $5.2 million |
TTM: trailing 12 months
We're not expecting Sunshine Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
Sunshine Biopharma's shares were split on a 1:20 basis on 7 August 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sunshine Biopharma shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Sunshine Biopharma shares which in turn could have impacted Sunshine Biopharma's share price.
Over the last 12 months, Sunshine Biopharma's shares have ranged in value from as little as $1.9 up to $265. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sunshine Biopharma's is -1.477. This would suggest that Sunshine Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Sunshine Biopharma has bucked the trend.
To put Sunshine Biopharma's beta into context you can compare it against those of similar companies.
Sunshine Biopharma, Inc. , a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1. 1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Check out the best-performing ETFs so far in 2025.